- Home
- ats conference coverage
Latest ATS Insights
Stay One Step
Ahead with Our Thorough ATS Coverage
The ATS Conference is a prominent annual event that brings together healthcare professionals, researchers, and industry leaders in the field of respiratory health. It serves as a platform for discussing advancements in diagnostics, treatments, and patient care strategies. The ATS Conference fosters collaboration and innovation to improve outcomes for patients with respiratory and related disorders.
Consulting Projects
Clients Served
Our team has analyzed thousands of scientific abstracts presented at each ATS Conference, capturing the latest updates and discoveries from diverse respiratory clinical trials. These insights play a crucial role in advancing therapeutic research and transforming approaches to patient care. Moreover, we have tracked social media platforms for pertinent ATS-related hashtags, helping clients make substantial progress in the respiratory field.
Experience
Stay ahead with exclusive ATS conference insights—reach out to us now!
Past ATS Events
ATS 2024: Key Insights and Analysis
Find out the list of future biomarkers and targets that are expected to enter in severe asthma space
ATS 2023 Conference Coverage
Dive deep into the positive results from the Phase III BOREAS trial evaluating DUPIXENT for COPD treatment
ATS 2022 International Conference
Uncover how aTyr Pharma finds its way to the untapped market of pulmonary sarcoidosis
Success Story
Case Studies
Conference coverage
Learn how a big pharma company leverages various respiratory conferences, such as ATS, ERS, JRS, and others, to stay ahead in the IPF therapeutic domain.
View Case Study →Conference coverage
Discover how a mid-sized European pharmaceutical company utilized in-depth ATS conference coverage to gain insights into the assets they were focused on.
View Case Study →Get in touch with us today to learn how we can provide ATS coverage exclusively for you!
Reports
Respiratory Domain Focussed Whitepaper and Newsletter
Why DelveInsight for Respiratory Conference Coverage?
Screening, categorization, and prioritization of abstracts based on areas of interest
Latest Highlights
Article
Pfizer’s ABRYSVO Outpaces GSK’s AREXVY with Expanded FDA Approval – But Can It Sustain the Momentum?
Pfizer’s ABRYSVO became the first and only RSV vaccine approved for use in adults under 50, offering the most extensive RSV vaccine coverage for adults. The label expansion announced on 22 October 2024 includes younger adults considered at higher risk for RSV-related lower respiratory tract disease (LRTD).
Oct 28, 2024
Get in Touch
Get Expert Consulation Now
With our extensive experience and deep expertise in respiratory, we are well-equipped to address your most pressing business challenges. Our comprehensive knowledge of the respiratory pipeline, detailed insights into market dynamics, and sharp understanding of marketing intricacies enable us to craft a highly effective strategy for your future success.
Connect with us to explore potential collaboration and discover how we can support your goals.